2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Profiling, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

6063 Limited prognostic impact of molecular MRD category and differential conditioning benefit in MRD-positive AML undergoing allo-HSCT

Ruixin Li, Xiaoyu Zhang, MD2, Xiaoxiao Ma3, Donglin Yang4, Yi He, MD5, Aimin Pang6, Erlie Jiang, MD7
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Objective:

Pre-transplant measurable residual disease (MRD) is an important prognostic factor in acute myeloid leukemia (AML). However, the prognostic impact of different molecular MRD markers associated with AML risk stratification remains unclear. This study aimed to evaluate the prognostic impact of different molecular MRD categories and the effect of conditioning regimens in AML patients with pre-transplant MRD positivity undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods:

We retrospectively reviewed 1,012 patients with AML who underwent allo-HSCT at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, between May 2015 and December 2024. A total of 316 patients who achieved complete remission before transplantation and had either molecular MRD positivity or multiparameter flow cytometry-MRD (MFC-MRD) positivity were included. Conditioning regimens mainly included busulfan/cyclophosphamide/fludarabine/cytarabine or idarubicin (BCFC/BCFI) and busulfan/cyclophosphamide/cladribine/melphalan (MCBC).

Results:

Among the 316 pre-transplant MRD-positive patients, 21.8% had MFC-MRD positivity alone, 32.9% had concurrent MFC-MRD and molecular MRD positivity, and 45.3% had molecular MRD positivity alone. Among molecular MRD-positive patients, core-binding factor (CBF) abnormalities, NPM1 mutations, intermediate-risk molecular genetic abnormalities, and adverse-risk molecular genetic abnormalities accounted for 26.3%, 10.4%, 2.2%, and 6.3%, respectively. A total of 173 patients were MFC-MRD positive before transplantation, of whom 39.8% also had molecular MRD positivity. BCFC/BCFI and MCBC conditioning were used in 59.5% and 32.0% of patients, respectively.

Among patients with molecular MRD positivity alone, no significant differences were observed among those with adverse-risk molecular genetic abnormalities, intermediate-risk molecular genetic abnormalities, CBF abnormalities, and NPM1 mutations in 2-year overall survival (OS; 74.2% vs 57.1% vs 76.6% vs 79.4%), disease-free survival (DFS; 75.9% vs 38.1% vs 76.3% vs 76.6%), cumulative incidence of relapse (CIR; 14.1% vs 19.0% vs 3.7% vs 12.3%), MRD relapse (18.0% vs 42.9% vs 4.8% vs 9.2%), or non-relapse mortality (NRM; 10.0% vs 42.9% vs 19.7% vs 11.4%).

Compared with patients with MFC-MRD positivity alone, those with concurrent MFC-MRD and molecular MRD positivity had inferior 2-year OS (38.6% vs 63.2%, P = 0.012) and DFS (34.7% vs 56.3%, P = 0.032), and a higher CIR (46.8% vs 29.8%, P = 0.049). Within the concurrent MFC-MRD and molecular MRD-positive subgroup, 2-year OS (31.7% vs 31.2% vs 41.6% vs 66.7%), DFS (27.5% vs 31.2% vs 35.7% vs 66.1%), CIR (50.8% vs 50.0% vs 44.2% vs 33.3%), MRD relapse (58.0% vs 56.2% vs 59.2% vs 33.3%), and NRM (21.7% vs 18.8% vs 20.6% vs 0%) did not differ significantly across adverse-risk, intermediate-risk, core-binding factor, and NPM1-mutated molecular MRD categories.

Among patients with pre-transplant molecular MRD positivity, BCFC/BCFI conditioning was associated with superior 2-year OS (81.7% vs 62.6%, P = 0.005), DFS (79.3% vs 63.5%, P = 0.021), and lower NRM (12.6% vs 30.3%, P = 0.007) compared with MCBC. In contrast, among patients with pre-transplant MFC-MRD positivity, and those with concurrent molecular MRD positivity, MCBC was associated with superior 2-year DFS (82.5% vs 49.3%, P = 0.014; 61.0% vs 41.6%, P = 0.046, respectively).

Conclusion:

The specific category of pre-transplant molecular MRD positivity was not significantly associated with transplant outcomes, regardless of MFC-MRD status. Concurrent molecular MRD and MFC-MRD positivity identified patients with poor prognosis. Conditioning benefit appeared to differ by MRD pattern: BCFC/BCFI was associated with better outcomes in molecular MRD-positive patients, whereas MCBC may benefit patients with MFC-MRD positivity, especially those with concurrent molecular MRD.

Ruixin Li: No relevant conflicts of interest to declare.